Analyst consensus rating
Agios Pharmaceuticals Analyst Rating: Buy
Direct answer
Agios Pharmaceuticals's consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $45.88.
Forecast evidence checked October 31, 2026.
Get free Agios Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $30.55
- Average price target
- $45.88
- High price target
- $72.00
- Low price target
- $32.00
- Low target gap
- +4.7%
- Target upside
- +50.2%
- High target gap
- +135.7%
- Target range width
- 130.9%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- October 31, 2026
- Valid through
- November 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Agios Pharmaceuticals?
Agios Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $45.88.
How far are Agios Pharmaceuticals's low and high targets from the recorded price?
The low target implies +4.7%, while the high target implies +135.7%.
How many analysts are included in Agios Pharmaceuticals's consensus?
The verified consensus includes 8 analysts.
How is Agios Pharmaceuticals's target upside or downside calculated?
The average target of $45.88 is divided by the recorded price of $30.55, then one is subtracted to produce +50.2%. This does not guarantee a future return.
When was Agios Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-31. The dataset is valid through 2026-11-07.